CRUK Scotland Institute is a research institute focused on understanding cancer mechanisms and developing novel cancer therapies. It is core-funded by Cancer Research UK.

CRUK Scotland Institute

Cancer Research UK Scotland Institute | 4,461 followers on LinkedIn. As one of Cancer Research UK’s core-funded institutes we carry out a programme of world-class science directed at understanding key aspects of cancer cell behaviour, and try to translate these discoveries into new therapies and diagnostic/prognostic tools to help cancer patients. The Institute benefits from close interactions with the University of Glasgow, including strong links with the University’s Institute of Cancer Sciences.

We occupy a magnificent research building that has allowed us to develop some state-of-the-art technologies in focused areas to underpin our key research themes.

Experienced Cancer Researcher with Project/Personnel Management Skills and an Aptitude for Scientific Writing

Nathalie Sphyris, PhD

Deputy Director; Professor, Mitochondrial Cancer Biology - School of Cancer Sciences, University of Glasgow

Stephen Tait

Group Leader at Cancer Research UK Scotland Institute Co-Director MRC Scotland Total Body PET Facility

David Lewis

Senior scientific officer-Beatson Institute CRUK

Catherine Ficken

Cancer Research UK Scotland Institute

Message from CRUK CRUK RESEARCHERS AND COVID-19: SHARE YOUR STORY How is COVID-19 affecting you as a researcher? How are you adapting to life in lockdown? Have you changed your research focus, or found innovative ways to collaborate? If you’re a Cancer Research UK-funded researcher, we want to hear from you. In an upcoming series, we plan to celebrate the resilience and resourcefulness of our community in the face of a global pandemic, as well as highlighting the challenges of being a researcher right now. And we want to hear your stories. Share your experience of the coronavirus crisis in two ways: · Contact us: If you’re a CRUK-funded researcher with a story to tell, drop us a line at researcher.comments@cancer.org.uk and we’ll be in touch. · Complete our short survey: Help us understand how our funded research community have adapted to our new normal. Fill out the survey bit.ly/2S6Zm5P . Read stories in the series as soon as they publish: follow us on Twitter @CRUKresearch #cancerresearchuk

Metric
Company Name	CRUK Scotland Institute
Symbol
MSH ID	UK:AC:CRUKSCOTLANDINSTITUTE
Market	PRIVATE
Sector	Healthcare & Health Services
Industry	Cancer Research
Country	GB
Stage
Employee Count
Website	crukscotlandinstitute.ac.uk
LinkedIn	the-beatson-institute-for-cancer-research
Founders

Metric
Market Cap
Enterprise Value
Monthly Web Traffic
Web Traffic Growth
Valuation
Raised Capital

Metric
Revenue
Revenue (LTM)
Revenue (NTM)
Gross Profit
EBITDA
Operating Income
Net Income
EPS
Diluted EPS
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin
Operating Profit Margin
EBITDA Margin
Net Profit Margin
Return on Equity
Return on Assets
Return on Capital Employed

AC

UK:AC:CRUKSCOTLANDINSTITUTE

CRUK Scotland Institute

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio
P/B Ratio
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio
EV Multiple

Metric
Days Sales Outstanding
Days Payables Outstanding
Days Inventory Outstanding
Operating Cycle
Cash Conversion Cycle
Asset Turnover

Metric
Operating Cash Flow
Free Cash Flow
Cash Flow to Debt
Operating Cash Flow/Sales
Free Cash Flow Yield

Metric
Cash & Equivalents
Accounts Receivable
Inventory
Goodwill
Debt to Capitalization
Debt to Assets
Current Ratio
Quick Ratio

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue
R&D to Revenue
SG&A to Revenue